Kestra Medical Technologies (NASDAQ:KMTS) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Kestra Medical Technologies (NASDAQ:KMTS) issued its quarterly earnings data on Tuesday. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08), FiscalAI reports. Kestra Medical Technologies had a negative return on equity of 60.60% and a negative net margin of 138.35%.The company had revenue of $28.64 million during the quarter.

Here are the key takeaways from Kestra Medical Technologies’ conference call:

• Revenue accelerated sharply in the fourth quarter to $28.6 million, up 66% year over year, and full-year revenue reached $95 million, up 59% from FY2025.
• Gross margin continued to expand to 54.8% in Q4, marking the 10th straight quarter of sequential improvement, and management still sees a path to 70%+ gross margins over the next few years.
• Commercial momentum remained strong with more than 6,300 ASSURE prescriptions in the quarter, 55% growth in new prescribers during FY2026, and sales territories increasing to about 130 from roughly 80 a year earlier.
• FY2027 guidance calls for 44% revenue growth to $137 million, supported by deeper penetration in existing accounts, new account activation, higher in-network mix, and better revenue cycle management.
• The company emphasized clinical evidence and product innovation, including ACE-PAS recognition in a Heart Rhythm publication, a new enhanced detection algorithm now shipping to all patients, and an expanded product pipeline aimed at further differentiating ASSURE.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $24.61 on Thursday. The stock’s 50-day moving average is $22.17 and its two-hundred day moving average is $22.73. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. Kestra Medical Technologies has a 1-year low of $13.25 and a 1-year high of $30.00. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -10.17 and a beta of 0.47.

Insider Activity

In other news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the completion of the transaction, the insider directly owned 395,467 shares of the company’s stock, valued at approximately $8,229,668.27. The trade was a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in shares of Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after purchasing an additional 2,529,851 shares during the last quarter. Brown Advisory Inc. increased its holdings in Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after buying an additional 428,996 shares during the last quarter. Alliancebernstein L.P. raised its stake in Kestra Medical Technologies by 13.7% in the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after buying an additional 179,885 shares in the last quarter. Eventide Asset Management LLC lifted its holdings in Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after buying an additional 65,288 shares during the last quarter. Finally, Franklin Resources Inc. lifted its holdings in Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after buying an additional 612,343 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts have recently commented on KMTS shares. Weiss Ratings upgraded Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 30th. The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. BTIG Research lifted their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $27.83.

Key Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: BTIG Research raised its price target on Kestra Medical Technologies to $32 from $30 and reiterated a Buy rating, signaling confidence in roughly 30% upside from the current share price. BTIG Raises Price Target on Kestra Medical Technologies
• Positive Sentiment: The company secured a $200 million non-dilutive financing facility, which should strengthen liquidity and help fund growth without immediately diluting shareholders. Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
• Positive Sentiment: Management issued FY2027 revenue guidance of about $137 million, slightly above Wall Street expectations, suggesting continued top-line growth momentum. Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
• Neutral Sentiment: The company reported fourth-quarter revenue of $28.64 million, which topped expectations, but the earnings call transcript and release largely reiterated the quarter’s operating details. Kestra Medical Technologies Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Kestra posted a quarterly loss of $0.67 per share, wider than the expected loss of $0.59, highlighting that profitability remains a challenge despite better-than-expected revenue. Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.